Volume 9 Supplement 1
Proceedings of 18th Pediatric Rheumatology European Society (PReS) Congress
Meeting abstracts
Edited by Rolando Cimaz, Pavla Dolezalova, Marco Gattorno, Hermann Girschick, Michael Hofer, Sue Maillard, Alberto Martini, Pierre Quartier, Carlos Rose, Johannes Roth, Rebecca ten Cate and Carine Wouters.
18th Pediatric Rheumatology European Society (PReS) Congress. Go to conference site.
Bruges, Belgium14-18 September 2011
Page 1 of 8
-
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O1
-
CD4+FOXP3+ regulatory T cells are abundantly present in inflamed muscle of patients with juvenile dermatomyositis
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O2 -
Overexpression of CREMαlpha accelerates onset and severity of auto-immune mediated disease in a murine model of lupus
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O3 -
Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O4 -
Sensitivity and specificity of current diagnostic guidelines in children with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O5 -
Recombinant IL1-RA in the early phase of systemic onset JIA: before the onset of arthritis
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O6 -
Functional human regulatory T cells fail to control autoimmune inflammation due to PKB/c-akt hyperactivation in effector cells
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O7 -
Characterising inflammatory markers in two childhood autoimmune diseases (JIA and JDM) pre and post methotrexate
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O8 -
Low levels of the nerve growth factor receptor TrkA in JIA: a possible defect in a novel anti-inflammatory mechanism
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O9 -
Can inflammatory markers predict response to methotrexate in JIA? Results from the CHARM study
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O10 -
Comparison of CNS vasculitis in children and adults; is this the same disease entity
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O11 -
MRI and ultrasound versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in JIA. Do these imaging techniques have an additional value?
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O12 -
Increased percentages of calprotectin and TNF-Α double-positive monocytes in the acute phase of Kawasaki disease
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O13 -
Clinical phenotype of neonatal lupus erythematosus relates to autoantibody level and gender
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O14 -
Preliminary validation of the paediatric vasculitis activity score (PVAS)
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O15 -
Long-term methotrexate efficacy in juvenile localized scleroderma
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O16 -
Defining clinical remission and clinically inactive disease in juvenile systemic lupus erythematosus (jSLE)
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O17 -
Patients with early-onset systemic juvenile idiopathic arthritis show more inflammation and worse outcome
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O18 -
Analysis of growth in female patients with pediatric-onset systemic lupus erythematosus
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O19 -
Subclinical cardiovascular abnormalities in patients with juvenile systemic lupus erythematosus
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O20 -
Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O21 -
Children with juvenile idiopathic arthritis currently followed in a tertiary care setting have a better psychosocial well-being than healthy peers
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O22 -
Treatment of methotrexate (MTX) intolerance: behavioural therapy, versus switch to parenteral MTX versus oral MTX
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O23 -
To evaluate the impact of a nurse-led JIA education program on parental satisfaction regarding knowledge of JIA and its management
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O24 -
Identification of Blau Syndrome disease signatures
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O25 -
Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O26 -
Safety and efficacy of ultrasound guided corticosteroid injections into temporomandibular joints in children with active juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O27 -
Etanercept in juvenile idiopathic arthritis: Who will benefit?
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O28 -
Effectiveness of anti-TNF-α agents in the treatment of refractory juvenile dermatomyositis
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O29 -
Characterization of tonsil infiltration and gene expression profile of innate sensors in PFAPA patients
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O30 -
Role of IL-1b in NLRP12-associated autoinflammatory disorders and resistance to anti-IL-1 therapy
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O31 -
International cohort study for pediatric Behçet’s Disease: update 2011
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O32 -
Akinra restores the defective IL-18 NK cell axis in steroid naïve systemic onset JIA patients
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O33 -
Creation of a cohort of French patients with chronic recurrent multifocal osteitis : preliminary results
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O34 -
The frequency of parent-reported motor coordination difficulties in children diagnosed with benign joint hypermobility syndrome
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O35 -
The development of a new service for the management of Non-inflammatory Musculoskeletal Pain
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O36 -
Analgesia for joint punctures in children - experiences with a nitrous oxide / oxygen mixture (LIVOPAN®)
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O37 -
Rilonacept (IL-1 TRAP) for treatment of colchicine resistant familial mediterranean fever (FMF): a randomized, multicenter double-blinded, alternating treatment trial
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O38 -
A novel mutatioin in the PSTPIP1 gene is associated with an autoinflammatory disease distinct from classical PAPA syndrome
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O39 -
Toll-like receptor 2 polymorphism in juvenile dermatomyositis
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O40 -
Safety and immunogenicity of human papillomavirus vaccination in juvenile patients with rheumatic diseases
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O41 -
Predictors of disability in children with inflammatory arthritis, two and three years after first presentation to paediatric rheumatology. Results from the childhood arthritis prospective study (CAPS)
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O42 -
Increasing self-efficacy – the effectiveness of a pain management programme for children and parents
Citation: Pediatric Rheumatology 2011 9(Suppl 1):O43 -
National CAPS (Cryopyrin-Associated Periodic Syndrome) Registry
Citation: Pediatric Rheumatology 2011 9(Suppl 1):P1 -
Amyloidosis in a child with Hyperimmunoglobulin D syndrome
Citation: Pediatric Rheumatology 2011 9(Suppl 1):P2 -
Cryopyrin-associated periodic syndromes (CAPS): report on two cases (Muckle-Wells syndrome (MWS) and CINCA/NOMID)
Citation: Pediatric Rheumatology 2011 9(Suppl 1):P3 -
Recurrent poliserositis succesfully treated with IL-1 receptor antagonist Anakinra
Citation: Pediatric Rheumatology 2011 9(Suppl 1):P4 -
Familial mediterranean fever and pauciimmune renal vasculitis: the role of IL-1 blockade (Anakinra)
Citation: Pediatric Rheumatology 2011 9(Suppl 1):P5 -
Sustained remission of Multicentric Castleman Disease in children treated with tocilizumab
Citation: Pediatric Rheumatology 2011 9(Suppl 1):P6 -
Interleukin-1 antagonists in Mevalonate Kinase Deficiency
Citation: Pediatric Rheumatology 2011 9(Suppl 1):P7
Official journal of
Annual Journal Metrics
-
Citation Impact
3.413 - 2-year Impact Factor (2021)
3.970 - 5-year Impact Factor (2021)
1.315 - Source Normalized Impact per Paper (SNIP)
1.051 - SCImago Journal Rank (SJR)Speed
54 days to first decision for all manuscripts (Median)
68 days to first decision for reviewed manuscripts only (Median)
Usage
901,346 Downloads (2022)
661 Altmetric mentions (2021)